Korro Bio(KRRO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Korro Reports First Quarter 2025 Financial Results and Provides Business Updates CAMBRIDGE, Mass., May 7, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical- stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2025 and provided a business update. Ram Aiyar, Ph.D., CEO and President of Korro, said, "We remain on tr ...